The GLP-1 Manufacturing Race Is a Supply Chain Problem, Not a Drug Problem
GLP-1 manufacturing is becoming the bottleneck that decides who can supply the next wave of obesity drugs, and capital is following the capacity. Eli Lilly committed $6B to a single manufacturing plant in Huntsville, Alabama, in December 2025 — the largest single-site pharmaceutical investment in state history. Amgen followed in April 2026 with a $900M … Read more